Blood Based Biomarker Market
Description
The term biomarker, or biological marker, refers to a broad range of measures that capture what is happening in a cell or organism at a given moment. Blood-based biomarkers can be effective in formulating new diagnostic and treatment proposals. Blood-based biomarkers have significant advantages of being time and cost-efficient
Market Dynamics
Key players operating in the global blood based biomarker market are focusing on adoption of growth strategies such as product launch, collaboration, and fund raise which are expected to drive the market growth during the forecast period. For instance, in September 2020, ONCOtracker, Inc., a West Hollywood-based oncology company and The Binding Site Group Ltd, provides specialist diagnostic products to clinicians and laboratory professionals worldwide, announced they have entered into an exclusive global license and collaboration agreement to develop a novel clinical laboratory test for measuring sBCMA, a novel blood-based biomarker, which has shown promise to monitor and predict outcomes for patients with common blood-based cancers including multiple myeloma (MM) and chronic lymphocytic leukemia (CLL) and other related conditions. Moreover, for instance, in April 2021, Sera Prognostics, a Women’s health company had secured US$100 m in Series E financing to advance the commercialization of its PreTRM test for premature birth risk. The PreTRM test is a clinically validated and commercially available blood-based biomarker test, which offers an early, precise, and individualized risk prediction for spontaneous preterm birth in asymptomatic singleton pregnancies.
Key features of the study
Market Dynamics
Key players operating in the global blood based biomarker market are focusing on adoption of growth strategies such as product launch, collaboration, and fund raise which are expected to drive the market growth during the forecast period. For instance, in September 2020, ONCOtracker, Inc., a West Hollywood-based oncology company and The Binding Site Group Ltd, provides specialist diagnostic products to clinicians and laboratory professionals worldwide, announced they have entered into an exclusive global license and collaboration agreement to develop a novel clinical laboratory test for measuring sBCMA, a novel blood-based biomarker, which has shown promise to monitor and predict outcomes for patients with common blood-based cancers including multiple myeloma (MM) and chronic lymphocytic leukemia (CLL) and other related conditions. Moreover, for instance, in April 2021, Sera Prognostics, a Women’s health company had secured US$100 m in Series E financing to advance the commercialization of its PreTRM test for premature birth risk. The PreTRM test is a clinically validated and commercially available blood-based biomarker test, which offers an early, precise, and individualized risk prediction for spontaneous preterm birth in asymptomatic singleton pregnancies.
Key features of the study
- This report provides an in-depth analysis of the Global Blood Based Biomarker Market, and provides market size (USD Bn) and compound annual growth rate (CAGR%) for the forecast period (2026-2033), considering 2025 as the base year
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
- It profiles key players in the global blood based biomarker market based on the following parameters – Company Highlights, Products Portfolio, Key Highlights, Financial Performance, Strategies
- Key companies covered as a part of this study include Diadem srl., Proteomedix, Cleveland Diagnostics, F. Hoffmann-La Roche Ltd, GENFIT, Nutech Cancer Biomarkers India Pvt Ltd, SysmOex Corporation, Minomic, Creative Diagnostics, Eisai Co., Ltd., and C2N Diagnostics
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
- The global blood based biomarker market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global blood based biomarker market
- By Type
- Screening Biomarker
- Diagnosis Biomarker
- Others
- By Disease
- Cancer
- Neurological Disorders
- Others
- By Application
- Diagnostics
- Drug Discovery
- Personalized Medicine
- By Region
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East & Africa
- GCC Countries
- Israel
- Rest of Middle East & Africa
- Key Players
- Diadem srl.
- Proteomedix
- Cleveland Diagnostics
- Hoffmann-La Roche Ltd
- GENFIT
- Nutech Cancer Biomarkers India Pvt Ltd
- SysmOex Corporation
- Minomic, Creative Diagnostics, Eisai Co., Ltd.
- C2N Diagnostics
Table of Contents
160 Pages
- 1. Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
- 2. Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market Snapshot, By Type
- Market Snapshot, By Disease
- Market Snapshot, By Application
- Market Snapshot, By Region
- Coherent Opportunity Map (COM)
- 3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Drivers
- Restraints
- Market Opportunities
- Impact Analysis
- Market Trends
- Key Developments
- Product Approval
- Collaboration/Merge/Acquisition
- Regulatory Landscape
- PEST Analysis
- Porter’s Five Forces Analysis
- Epidemiology
- Robust Pipeline Analysis
- 4. Blood Based Biomarkers Market, By Type, 2026 – 2033, (USD Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2026– 2033
- Segment Trends
- Screening Biomarker
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026–2033, (USD Bn)
- Diagnosis Biomarker
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026–2033, (USD Bn)
- Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026–2033, (USD Bn)
- 5. Blood Based Biomarkers Market, By Disease, 2026 – 2033, (USD Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2026 – 2033
- Segment Trends
- Cancer
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026–2033, (USD Bn)
- Neurological Disorders
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026–2033, (USD Bn)
- Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026–2033, (USD Bn)
- 6. Blood Based Biomarkers Market, By Application, 2026 – 2033, (USD Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2026 – 2033
- Segment Trends
- Diagnostics
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026–2033, (USD Bn)
- Drug Discovery
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026–2033, (USD Bn)
- Personalized Medicine
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026–2033, (USD Bn)
- 7. Blood Based Biomarkers Market, By Region, 2026 – 2033, (USD Bn)
- Introduction
- Market Share Analysis, By Region, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, For Regions, 2026–2033
- Regional Trends
- North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Type, 2026 - 2033, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Disease, 2026 - 2033, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2026 - 2033, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2026 – 2033, (USD Bn)
- U.S.
- Canada
- Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Type, 2026 - 2033, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Disease, 2026 - 2033, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2026 - 2033, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2026 – 2033, (USD Bn)
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Type, 2026 - 2033, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Disease, 2026 - 2033, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2026 - 2033, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2026 – 2033, (USD Bn)
- U.K.
- Germany
- Italy
- France
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Type, 2026 - 2033, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Disease, 2026 - 2033, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2026 - 2033, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2026 – 2033, (USD Bn)
- China
- India
- Japan
- ASEAN
- Australia
- South Korea
- Rest of Asia Pacific
- Middle East
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Type, 2026 - 2033, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Disease, 2026 - 2033, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2026 - 2033, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2026 – 2033, (USD Bn)
- GCC
- Israel
- Rest of Middle East
- Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Type, 2026 - 2033, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Disease, 2026 - 2033, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2026 - 2033, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2026 – 2033, (USD Bn)
- North Africa
- Central Africa
- South Africa
- 8. Competitive Landscape
- Heat Map Analysis
- Market Share Analysis
- Company Profile
- Diadem srl.
- Company Highlights
- Product Portfolio
- Financial Performance
- Recent Highlights
- Market Strategies
- Proteomedix
- Company Highlights
- Product Portfolio
- Financial Performance
- Recent Highlights
- Market Strategies
- Cleveland Diagnostics
- Company Highlights
- Product Portfolio
- Financial Performance
- Recent Highlights
- Market Strategies
- F. Hoffmann-La Roche Ltd
- Company Highlights
- Product Portfolio
- Financial Performance
- Recent Highlights
- Market Strategies
- GENFIT
- Company Highlights
- Product Portfolio
- Financial Performance
- Recent Highlights
- Market Strategies
- Nutech Cancer Biomarkers India Pvt Ltd
- Company Highlights
- Product Portfolio
- Financial Performance
- Recent Highlights
- Market Strategies
- SysmOex Corporation
- Company Highlights
- Product Portfolio
- Financial Performance
- Recent Highlights
- Market Strategies
- Minomic
- Company Highlights
- Product Portfolio
- Financial Performance
- Recent Highlights
- Market Strategies
- Creative Diagnostics
- Company Highlights
- Product Portfolio
- Financial Performance
- Recent Highlights
- Market Strategies
- Eisai Co., Ltd.
- Company Highlights
- Product Portfolio
- Financial Performance
- Recent Highlights
- Market Strategies
- C2N Diagnostics
- Company Highlights
- Product Portfolio
- Financial Performance
- Recent Highlights
- Market Strategies
- Analyst Views
- 9. Section
- References
- Research Methodology
- About Us
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
